Skip to main content Skip to navigation

[University home]

School of Medicine

Dr Ian Hampson PhD

Photograph of Ian Hampson

Non-Clinical Senior Lecturer in Viral Oncology

Cancer & Enabling Sciences
Research Floor
St Mary's Hospital
Oxford Road
Manchester
M13 9WL

 

Role

Dr Ian N. Hampson was appointed senior lecturer and head of the newly formed University of Manchester Gynaecological Oncology laboratories at St Mary’s Hospital in 1997. Since their commissioning the gynaecological oncology Laboratories have expanded from one laboratory to four and are currently staffed by one lecturer, three post doctoral scientists and 9 PhD students. The groups’ main research goal is to provide new understanding of mechanisms of viral carcinogenesis and it now has a unique collection of human tumour virus oncoproteins for this purpose. The group has extensive experience in many aspects of both molecular and cellular biology in order to investigate gene function, gene regulation and gene expression. Molecular cloning, plasmid construction, quantitative PCR, protein immuno-detection, yeast two hybrid, targeted gene silencing and gene transfer, are techniques in common use in the laboratories. In recent years, the portfolio of the gynaecological oncology group has expanded to encompass work on other tumour viruses such as polyoma, HBV/HCV and HTLV1. The interests of the group are thus quite broad with the general theme to exploit the results of basic research to develop new approaches for both the diagnosis and treatment of virally induced cancers. This is best exemplified by the recent publicity surrounding the groups discovery of the potential new use for the orally admnistered HIV drug lopinavir as a topical treatment for human papilloma virus related pre cancerous disease of the cervix. See: BBC News 1, BBC News 2

 

Memberships of Committees and Professional Bodies

Member of the IAEA Working Party to Improve Radiotherapy Outcome in HIV+ve Women with Cervical Cancer 

Qualifications

PhD.

 

Publications

2011

  • Batman G, Oliver AW, Zehbe I, Richard C, Hampson L, Hampson IN. (2011). Lopinavir up-regulates expression of the antiviral protein ribonuclease L in human papillomavirus-positive cervical carcinoma cells. Antiviral Ther, 16(4), 515-525. eScholarID:127033 | DOI:10.3851/IMP1786
  • Oliver AW, He X, Borthwick K, Donne AJ, Hampson L, Hampson IN. (2011). The HPV16 E6 binding protein Tip-1 interacts with ARHGEF16, which activates Cdc42. Brit J Cancer, 104(2), 324-331. eScholarID:127031 | DOI:10.1038/sj.bjc.6606026
  • Zehbe I, Richard C, Lee KF, Campbell M, Hampson L, Hampson IN. (2011). Lopinavir shows greater specificity than zinc finger ejecting compounds as a potential treatment for human papillomavirus-related lesions. Antiviral Res, 91(2), 161-166. eScholarID:127032 | DOI:10.1016/j.antiviral.2011.05.016

2010

  • Dong-Hyun Kim, Roger M. Jarvis, Yun Xu, Anthony W. Oliver, J. William Allwood, Lynne Hampson, Ian N. Hampson, Royston Goodacre. (2010). Combining metabolic fingerprinting and footprinting to understand the phenotypic response of HPV16 E6 expressing cervical carcinoma cells exposed to the HIV anti-viral drug lopinavir. The Analyst, in press, eScholarID:80473 | DOI:10.1039/b923046g
  • Donne AJ, Hampson L, Homer JJ and Hampson IN. (2010). The role of HPV type in recurrent respiratory papillomatosis. Int J Pediatric Otolaryngology, 74, 7-14. eScholarID:35000 | DOI:10.1016/j.ijporl.2009.09.004
  • Hye-Jin Shin, Joo-Young Kim, Lynne Hampson, Hongryull Pyo, Hye Jung Baek, Stephen A. Roberts, Jolyon H. Hendry, & Ian N. Hampson. (2010). Human Papillomavirus 16 E6 increases the radiosensitivity of p53-mutated cervical cancer cells associated with up-regulation of aurora A. International Journal of Radiation Biology, in press, eScholarID:80474 | DOI:10.3109/09553002.2010.484477
  • Kim DH, Jarvis RM, Allwood JW, Batman G, Moore RE, Marsden-Edwards E, Hampson L, Hampson IN, Goodacre R. (2010). Raman chemical mapping reveals site of action of HIV protease inhibitors in HPV16 E6 expressing cervical carcinoma cells. Anal & Bioanal Chem, 398(7-8), 3051-3061. eScholarID:127030 | DOI:10.1007/s00216-010-4283-6

2009

  • Donne A, Hampson L, He X, Rothera M, Homer JJ, Hampson IN. (2009). Cidofovir induces an increase in levels of low-risk and high-risk HPV E6. Head Neck, 31( 7), eScholarID:1d19659 | DOI:10.1002/hed.21043
  • Donne AJ, Hampson L, He XT, Day PJR, Salway F, Rothera MP, Homer JJ and Hampson IN (In-press). Potential risk factors associated with the use of cidofovir to treat benign HPV related disease. Antiviral Therapy, eScholarID:34974 | DOI:10.3851/IMP1421
  • Hampson L, He XT, Oliver AW, Hadfield JA, Kemp T, Butler J, McGown A, Kitchener HC, Hampson IN. (2009). Analogues of Y27632 increase gap junction communication and suppress the formation of transformed NIH3T3 colonies. Bristish Journal of Cancer, 101(5), 829-839. eScholarID:34939 | DOI:10.1038/sj.bjc.6605208

2007

  • Donne A, Hampson L, He X, Rothera MP, Homer JJ, Hampson IN. (2007). Effects of cidofovir on a novel cell based test system for recurrent respiratory papillomatosis. Head and neck - E-Pub ahead of print, In Press 2007, eScholarID:1d13088
  • Silva, P, West, CML, Slevin, NJ, Valentine, HR, Ryder, WDJ, Hampson, L, Bibi, R, Sloan, P, Thakker, NS, Homer, J, Hampson, IN. (2007). Tumor expression of major vault protein (MVP) is an adverse prognostic factor for radiotherapy outcome in oropharyngeal carcinoma. Int J Rad Oncol Biol Phys, 69, eScholarID:1d15644

2006

  • Hampson L, Kitchener HC, Hampson IN. (2006). Specific HIV protease inhibitors inhibit the ability of HPV16 E6 to degrade p53 and selectively kill E6 dependent cervical carcinoma cells in vitro. Antiviral Therapy, 11 (6), 813-825. eScholarID:1d13089

2004

  • Hampson L, Li CS, Oliver AW, Kitchener HC, Hampson IN. (2004). The PDZ protein Tip-1 is a gain of function target of the HPV16 E6 oncoprotein. Int J. Oncol, 25(5):, 1249-56. eScholarID:1d10171
  • He X, Brenchley PEC, Jayson G-, Hampson L, Davies JM, Hampson IN. (2004). Hypoxia increases heparanase dependent tumor cell invasion which can be inhibited by anti-heparanase antibodies. Cancer Res, 64(11), 3928-33. eScholarID:1d10169 | DOI:10.1158/0008-5472.CAN-03-2718

2003

  • Li CS, Issa R, Kumar P, Hampson IN, Bernabeu C, Kumar S. (2003). CD105 prevents apoptosis in hypoxic endothelial cells. J Cell Sci, 116, 2677-2685. eScholarID:1d6379
  • Morris EC, Daffron TR, Forsyth SL, Missen MA, Horvath AJ, Hampson L, Hampson IN, Carrell RW, Coughlin PB. (2003). Murine Serpin 2A is a redox sensitive intracellular protein. Biochem J, 371 (1), 165-73. eScholarID:1d6377

2002

  • Martin-Hirsch P, Kitchener HC, Hampson IN. (2002). Photodynamic therapy of lower genital tract neoplasia. Gynecol Oncol, 84(1), 187-9. eScholarID:1d6376
  • Xiaotong H, Hannocks MJ, Hampson IN, Brunner GG. (2002). GPI-specific phospholipase D mRNA expression in tumor cells of different malignancy. Clin Exp Metastasis, 276(12), 291-299. eScholarID:1d3840

2001

  • Abdel-Hady E.S, Martin-Hirsch P, Duggan-Keen M, Stern PL, Moore JV, Corbitt G, Kitchener HC, Hampson IN. (2001). Immunological and viral factors associated with the response of vulval intraepithelial neoplasia to photodynamic therapy. Cancer Res, 61, 192-6. eScholarID:1d3009
  • Hampson L, El Hady ES, Moore JV, Kitchener HC, Hampson IN. (2001). The HPV16 E6 and E7 proteins and the radiation resistance of cervical carcinoma. Faseb Journal, 15(8), 1445-1447. eScholarID:1d3849 | DOI:10.1096/fj.00-0728fje
  • Hampson L, Hampson IN, Babichuk CK, Cotter L, Bleackley RC, Dexter TM, Cross MA. (2001). A minimal serpin promoter with high activity in haematopoietic progenitors and activated T cells. Hematol J, 2(3), 150-160. eScholarID:1d3852

2000

  • Li C, Hampson IN, Hampson L, Kumar P, Bernabeu C, Kumar S. (2000). CD105 antagonizes the inhibitory signaling of transforming growth factor beta1 on human vascular endothelial cells. FASEB J, 14(1), 55-64. eScholarID:1d3836
  • Stern PL, Brown MD, Stacey S.N, Kitchener HC, Hampson IN, Abdel-Hady E.S, Moore JV. (2000). Natural HPV immunity and vaccination strategies. J Clin Virol, 19, eScholarID:1d3076

1999

  • Sugimoto, M, Nakamura, T, Ohtani, N, Hampson, L, Hampson, IN, Shimamoto, A, Furuichi, Y, Okumura, K, Niwa, S, Taya, Y, Hara, E. (1999). Regulation of CDK4 activity by a novel CDK4-binding protein, p34(SEI-1). Genes Dev, 13(22), 3027-3033. eScholarID:1d3830

Top of page

| Skip to main content | Skip to navigation | Skip to Search |